Author: Columbia SPS

Notwithstanding that the U.S. Food and Drug Administration (FDA) has twice designated psilocybin a Breakthrough Therapy—first for treatment-resistant depression and then for major depressive disorder, the U.S. Drug Enforcement Administration (DEA) has steadfastly refused to even initiate the process for rescheduling the drug. In early 2021, Dr. Sunil Aggarwal and Advanced Integrative Medical Science Institute, PLLC asked the DEA how he might obtain psilocybin for therapeutic use under Right to Try laws. In response, DEA said it had no authority to permit such uses because psilocybin is a schedule I drug permitted for research use only. DEA’s refusal to accommodate…